The company states: “John Fowler will be resigning from his role as Chief Executive Officer effective November 7, 2023, and Christopher Kirk, Ph.D. has been appointed as Chief Executive Officer. Dr. Kirk is a co-founder and member of the Board of Directors and previously served as Kezar’s President and Chief Scientific Officer from March 2015 to April 2023. Mr. Fowler will continue as a member of Kezar’s Board of Directors. In addition, Noreen Roth Henig, M.D., will be stepping down as Chief Medical Officer effective October 6, 2023. Zung To, SVP, Clinical Development Operations, will assume responsibilities for clinical trial execution and will oversee development operations.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KZR:
- Kezar Life Sciences price target raised to $20 from $18 at H.C. Wainwright
- Kezar Life Sciences enters into collaboration pact with Everest Medicines
- Kezar Life Sciences downgraded to Equal Weight from Overweight at Wells Fargo
- Kezar Life Sciences price target lowered to $18 from $19 at H.C. Wainwright
- Kezar Life Sciences reports Q2 EPS (34c), consensus (32c)
